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Theiler’s virus infection of the CNS induces an immune-mediated demyelinating disease in susceptible mouse strains and serves as a
relevant infection model for human multiple sclerosis (MS). Cannabinoids may act as immunosuppressive compounds that have shown
therapeutic potential in chronic inflammatory disorders. Using the Theiler’s murine encephalomyelitis virus model, we report here that
treatment with the synthetic cannabinoids WIN 55,212–2, ACEA, and JWH-015 during established disease significantly improved the
neurological deficits in a long-lasting way. At a histological level, cannabinoids reduced microglial activation, abrogated major histo-
compatibility complex class II antigen expression, and decreased the number of CD4 infiltrating T cells in the spinal cord. Both recovery
of motor function and diminution of inflammation paralleled extensive remyelination. Overall, the data presented may have potential
therapeutic implications in demyelinating pathologies such as MS; in particular, the possible involvement of cannabinoid receptor CB2
would enable nonpsychoactive therapy suitable for long-term use.
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Introduction
Multiple sclerosis (MS) is the most common chronic inflamma-
tory, demyelinating disease of the CNS in humans and is charac-
terized by neurological deficits including sensory deficits, motor
weakness, tremor, and ataxia. Demyelination is considered to
occur as a consequence of a chronic inflammation in which cir-
culating T cells and macrophages infiltrated into the CNS get
involved in the development of the demyelinated plaques that
characterize the disease (Noseworthy et al., 2000). The mecha-
nisms of the immune-mediated injury of myelin sheaths are
thought to involve an indirect bystander injury and an autoim-
mune response against myelin epitopes. The etiology of MS is still
unknown, but epidemiological studies suggest a role for viruses
in triggering the disease (Johnson, 1994). Several viruses have
been shown to induce CNS demyelination in animals, and Thei-
ler’s virus provides the best studied model. Theiler’s murine en-
cephalomyelitis virus (TMEV) is a picornavirus natural pathogen
in mice that, when injected intracerebrally in susceptible strains,
induces a chronic, progressive, demyelinating disease that resem-
bles progressive MS (Dal Canto and Lipton, 1977). An immune
response directed against viral and myelin epitopes takes place
in the CNS of TMEV-infected mice (Miller et al., 1997), and
this event is considered to be the cause of the TMEV-induced
demyelinating disease (TMEV-IDD). Mice exhibit several
clinical deficits, including progressive impaired motor coor-
dination, incontinence, and paralysis associated with axonal
loss and electrophysiological abnormalities (McGavern et al.,
2000).
Cannabinoids, the bioactive components of Cannabis sativa,
are immunosuppressors by affecting cell function (Zhu et al.,
1998; Mc Coy et al., 1999) and by inhibiting proinflammatory
soluble mediators (Klein et al., 2000). On this basis, cannabidiol,
the nonpsychoactive cannabinoid, ameliorated chronic inflam-
mation in a mouse model of rheumatoid arthritis (Malfait et al.,
2000). In experimental autoimmune encephalomyelitis (EAE),
9-tetrahydrocannabinol (THC), the major psychotropic con-
stituent of marijuana, was effective in delaying the onset of dis-
ease when administered before induction (Lyman et al., 1989).
Synthetic cannabinoids also reduce spasticity and tremor in mice
with chronic relapsing EAE (Baker et al., 2000), accordingly to
their actions on pain and motor pathways in the CNS. Limited
clinical studies have suggested beneficial effects of cannabinoids
(for review, see Pertwee, 2002), and the possible role of the endo-
cannabinoid system in MS symptomatology has also been dis-
cussed (Di Marzo et al., 2000).
Cannabinoids are hydrophobic compounds that exert most of
their actions via the activation of specific G-protein-coupled re-
ceptors. To date, two cannabinoid receptors have been cloned
and characterized, cannabinoid type 1 receptor (CB1) and canna-
binoid type 2 receptor (CB2), although additional receptors may
exist (Matsuda et al., 1990; Di Marzo et al., 2001). The CB1 recep-
tor is expressed primarily in the CNS (Herkenham et al., 1990)
and is responsible for the psychotropic effects of cannabinoids,
whereas the CB2 receptor is expressed predominantly in immune
Received Nov. 1, 2002; revised Dec. 23, 2002; accepted Dec. 27, 2002.
This work was supported by grants from the Ministerio de Ciencia y Tecnologı´a (Spain, SAF-2001/1246). We
gratefully appreciate Dr. R. P. Roos (University of Chicago) for delivery of Theiler’s virus. We express our gratitude to
E. Baides, C. Bailo´n, and C. Herna´ndez for their excellent technical assistance.
Correspondence should be addressed to Carmen Guaza, Cajal Institute, Consejo Superior de Investigaciones
Cientı´ficas, Avenida Doctor Arce 37, 28002 Madrid, Spain. E-mail: cgjb@cajal.csic.es.
Copyright © 2003 Society for Neuroscience 0270-6474/03/232511-06$15.00/0
The Journal of Neuroscience, April 1, 2003 • 23(7):2511–2516 • 2511
cells (Bouaboula et al., 1993; Munro et al., 1993). Nevertheless,
CB1 receptor expression is also reported in immune cells (Ga-
liegue et al., 1995). Several endogenous lipids have been isolated
and characterized as natural ligands for both receptors (Devane et
al., 1992; Mechoulam et al., 1995), and an endocannabinoid sys-
tem is known to operate, but its regulation and functions are not
yet well understood (for review, see Piomelli et al., 2000).
Our study reports a therapeutic effect of synthetic cannabi-
noids on TMEV-IDD. Cannabinoid treatment during estab-
lished clinical disease restores motor coordination, diminishes
inflammation, and promotes remyelination in TMEV-infected
mice.
Materials and Methods
Animals and Theiler’s virus inoculation. We used female SJL/J mice, sus-
ceptible to TMEV-IDD development, from our in-house colony (Cajal
Institute, Madrid, Spain), maintained on food and water ad libitum in a
12 hr light/dark cycle. Four-week-old mice were inoculated intracere-
brally in the right cerebral hemisphere with 10 6 pfu of BeAn TMEV strain
in 30 l of DMEM supplemented with 10% of FCS as previously de-
scribed (Lledo´ et al., 1999). Handling of animals was performed in com-
pliance with the guidelines of animal care set by the European Union
(86/609/EEC).
Evaluation of motor coordination. To evaluate neurological deficits of
mice, we used the rotarod test, which measures balance, coordination,
and motor control. The rotarod apparatus (Ugo Basile, Comerio, Italy)
consists of a suspended rod able to run at constant or at accelerating
speed. All mice were exposed to a training period at constant speed to
familiarize them with the apparatus before cannabinoid treatment and at
accelerating speed while the test was being performed. Data were col-
lected from mouse rotarod performance 1 d before the beginning of
treatment, 1 d after the end of the treatment, and 25 d later. The trial was
terminated when mice fell from the apparatus or after a maximum of 5
min. We analyzed data with a two-way ANOVA and Student’s t test.
Experimental procedure. At 60 d after TMEV infection, neurological
dysfunction was tested by the rotarod assay, and mice were assigned to
four groups, with initially no significant differences between them in
their ability to perform the rotarod test. Mice from these groups were
injected intraperitoneally once a day for 10 d with WIN 55,212–2 (non-
selective CB1/CB2 agonist), ACEA (1400-fold CB1 selectivity over
CB2), JWH-015 (23-fold CB2 selectivity over CB1), or vehicle. Doses
were calculated based on their receptor binding affinities, but this esti-
mate does not take account of pharmacokinetics of the individual com-
pounds (Pertwee, 1999). We evaluated effects of WIN 55,212–2 and
ACEA on motor function by testing spontaneous locomotor activity (Ac-
tivity Monitor System; Omnitech Electronics, Columbus, OH). Naive
SJL/J mice were injected intraperitoneally either with 5 mg/kg of WIN
55,212–2, 2.5 mg/kg of ACEA, or the appropriate vehicle and immedi-
ately introduced into the activity cage for a 60 min session. Mice injected
with WIN-55,212–2 displayed lower locomotor response than controls,
but no typical signs of catalepsy, as frozen postures or immobility were
observed (our unpublished results). To avoid potential habituation, can-
nabinoid agonist doses were increased through time as treatment ad-
vanced as follows: 2.5 mg/kg of WIN 55,212–2 for 3 d, 3.75 mg/kg on days
4 – 6, and 5 mg/kg on days 7–10. WIN 55,212–2 doses were based on a
previous report (Baker et al., 2000). ACEA doses were 1.25 mg/kg on days
1–3, 1.9 mg/kg on days 4 – 6, and 2.5 mg/kg on the last 4 d of treatment.
JWH-015 was injected at 0.6 mg/kg for 3 d, 0.9 mg/kg on days 4 – 6, and
1.2 mg/kg on the last 4 d. Vehicle-injected mice received a solution of 5%
BSA and 0.2% DMSO in PBS. The number of mice for each treatment
was 12; half were killed to process the spinal cord the day after treatment
termination, and the remainder were maintained for 25 d to reach 5
weeks from the beginning of treatment; this period is considered optimal
to evaluate remyelination induced by any event (Warrington et al., 2000).
Tissue processing. Mice were anesthetized by intraperitoneal pentobar-
bital administration and perfused transcardially with 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB). Spinal cords were collected and
divided into five segments. From each segment,1 mm was postfixed in
2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M PB for 1 hr,
stained with 1% osmium tetraoxide in water for 1 hr, and embedded in
Araldite epoxy resin (TAAB, Aldermaston, UK). Tissue was then cut with
an ultramicrotome to obtain 1 m semithin sections and stained with
toluidine blue. The remaining tissue was postfixed in 4% paraformalde-
hyde in 0.1 PB, cryoprotected with a 30% solution of sucrose in 0.1 PB,
and frozen in dry ice. We then obtained 35-m-thick coronal cryostat
sections and processed them to visualize microglia/macrophages using
Mac-1 anti-CD11b antibody (Serotec, Oxford, UK), CD4 T cells (BD
PharMingen, San Diego, CA) and major histocompatibility complex
(MHC) class II antigen expression using OX-6 anti H-2A class II anti-
body (Serotec). Immunostaining was visualized with Alexa-conjugated
secondary anti-mouse and anti-rat antibodies (Molecular Probes, Eu-
gene, OR). Negative controls for MHC class II detection were performed,
and immunostaining was absent in microglial cells.
Determination of reactive microglial cell number. To determine the
number of microglia with reactive morphology, five randomly selected
ventral spinal cord images per mouse at different levels were obtained by
confocal microscopy, with constant laser beam intensity and photode-
tector sensitivity. Images were analyzed with NIH Image software fixed to
detect Mac-1 cells larger than 25 m 2, a size we consider as reactive
microglia. To confirm that this was a correct size threshold, we analyzed
spinal cords from sham mice, and the software detected no cells in spinal
cord, in which all microglial cells were resting. Moreover, reactive micro-
glia detected by this method showed the same labeling intensity in vehi-
cle-treated compared with cannabinoid-treated mice. Data were
analyzed with one-way ANOVA followed by Tukey’s multiple com-
parison test.
Determination of CD4. To determine CD4 cell number, we counted
positive cells in four random microscopic fields using a 40 objective.
Five coronal sections were quantified per mouse at different spinal cord
levels. The four fields counted per section were always two from the
ventral and two from the dorsal region; two fields were from one hemi-
sphere and two from the other. We performed one-way ANOVA fol-
lowed by Tukey’s multiple comparison test with data obtained.
Quantitation of spinal cord demyelination. Toluidine blue-stained
semithin cross sections (1-m-thick) of cervical, thoracic, and lumbar
spinal cord were used for quantification. We counted both remyelinating
fibers (a thin myelin sheath compared with normally myelinated axon
fibers) and demyelinated axons (naked axons devoid of myelin) using a
100 objective. Counts were made in random fields within affected de-
myelinating areas in lateral, anterolateral, and anterior columns (the
effect was minimal in the posterior column). We analyzed six animals per
treatment, five sections per mouse, and five fields per area in each hemi-
sphere. To determine statistical differences, we performed one-way
ANOVA and Tukey’s post-test.
Results
Cannabinoid agonist treatment improves motor function on
established neurological symptomatology
Several studies correlate poor ability to perform rotarod test with
demyelination induced by TMEV infection (McGavern et al.,
1999). TMEV-infected mice exhibited reduced ability in rotarod
performance before cannabinoid treatment compared with sham
mice (Fig. 1). A two-way ANOVA revealed a significant effect of
treatment ( p 0.001), time ( p 0.001), and treatment time
interaction ( p  0.001). To evaluate the effect of cannabinoids
compared with the pretreatment situation, we performed Stu-
dent’s t test within each cannabinoid-treated group. One day
after a 10 d treatment protocol with the CB1/CB2 nonselective
cannabinoid agonist WIN 55,212–2, mice showed increased abil-
ity to perform the test correctly ( p 0.001); this effect was also
observed 25 d after cessation of treatment ( p  0.001). The se-
lective CB1 agonist ACEA also increased the ability of TMEV-
infected mice to perform the rotarod assay 1 d after the end of the
treatment ( p  0.01) as well as at 25 d ( p  0.01). The CB2
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selective agonist JWH-015, although it did not improve the mo-
tor ability of TMEV-infected mice to values similar to those of
WIN 55,212–2 and ACEA, also improved rotarod performance at
1 d ( p  0.001) and 25 d after treatment ( p  0.05). Thus, all
cannabinoids used induce functional recovery of TMEV-infected
mice that is maintained for at least 25 d after the termination of
treatment.
Cannabinoid agonists reduce microglial activation in
TMEV-infected mice
Microglial cells in the spinal cord of TMEV-infected mice
showed a reactive morphology in white and gray matter; 10 d
treatment with WIN 55,212–2, ACEA, or JWH-015 markedly
switched their morphology toward a resting one (Fig. 2a). This
effect was observed 1 d after treatment and was maintained for
at least 25 d after treatment (Fig. 2a). Quantification of reac-
tive microglia within the spinal cord and statistical analysis
showed that the three cannabinoid agonists induced a signif-
icant reduction ( p  0.001 for all agonists) in the number of
reactive microglial cells, both 1 and 25 d after the end of treat-
ment (Fig. 2b).
Macrophage/microglial cells can process and present mye-
lin epitopes, in association with MHC class II molecules, to
CD4 T cells within the CNS of TMEV-infected mice (Katz-
Levy et al., 1999). Double immunostaining for Mac-1 and
H-2A (SJL/J MHC class II haplotype) revealed a predominant
colocalization of MHC class II antigen expression on Mac-1
cells in the white and gray matter of TMEV-infected mice
spinal cords (Fig. 2c). One day after cannabinoid treatment,
positive immunostaining for MHC class II almost disappeared
in microglial cells with all three agonists. Importantly, this
effect did not diminish by 25 d after the end of treatment
(Fig. 2c).
Cannabinoid treatment reduces the number of CD4
infiltrated T cells in the spinal cord of
TMEV-infected mice
TMEV-infected mice exhibited CD4 in-
filtrated T cells within spinal cord white
and gray matter (Fig. 3a). Cannabinoid
treatment caused a significant reduction
in the number of CD4 T cells in the spi-
nal cord 1 d after treatment ( p  0.05
for WIN 55,212–2; p  0.001 for ACEA
and JWH-015), as well as at 25 d after
treatment ( p  0.05 for WIN 55,212–2
and JWH-015; p 0.01 for ACEA) (Fig.
3b). Therefore, treatment of TMEV-
infected mice with cannabinoids for
10 d reduced CD4 T cell infiltration in
spinal cord for at least 25 d after treat-
ment cessation.
Cannabinoid agonists promote
remyelination in TMEV-infected mice
Spinal cords of TMEV-infected mice
showed disperse demyelination (Fig. 4a),
preferentially distributed in anterior, an-
terolateral, and lateral columns. The
number of axons affected (demyelinated
plus remyelinated) in vehicle-treated and
cannabinoid-treated mice was not signifi-
cantly different, indicating that myelin le-
sions were similar in the different groups
(data not shown). In spinal cords from
cannabinoid-treated mice, however, there
was a reduction in the number of demyeli-
nated axons and a significant increase in the
Figure 1. Cannabinoids induce long-term improvement of motor function. Data from the
rotarod assay show a significant increase in motor function of WIN 55,212–2-treated (dose
schedule: 2.5 mg/kg for 3 d, 3.75 mg/kg on days 4 – 6, and 5 mg/kg on days 7–10), ACEA-
treated (dose schedule: 1.25 mg/kg on days 1–3, 1.9 mg/kg on days 4 – 6, and 2.5 mg/kg on the
last 4 d of treatment), and JWH-015-treated (dose schedule: 0.6 mg/kg for 3 d, 0.9 mg/kg on
days 4 – 6, and 1.2 mg/kg on the last 4 d) mice 1 d after the end of the 10 d treatment protocol,
which is maintained for at least 25 d after cessation of treatment. (***p 0.001 vs vehicle;
**p 0.01 vs vehicle; *p 0.05 vs vehicle).
Figure 2. Cannabinoids inhibit microglial activation. a, Confocal images with constant laser beam and photodetector sensitivity
of microglia/macrophages (CD11b cells) in ventral spinal cord sections. Microglial cells in vehicle-treated mice show a reactive
morphology at 1 and 25 d after treatment. In contrast, WIN 55,512–2, ACEA, and JWH-015 treatments markedly inhibit reactive
morphology of microglia at 1 and 25 d after treatment. Scale bar, 50 m. b, Treatment with cannabinoid agonists reduce the
number of reactive microglial cells in the spinal cord at 1 and 25 d after treatment (***p 0.001 vs vehicle). c, Confocal images
with constant laser beam and photodetector sensitivity of microglial MHC class II antigen expression. CD11b is shown in green, and
the MHC class II complex is shown in red. Note antibody colocalization ( yellow) in vehicle-treated mice and the presence of cells
other than microglia expressing MHC class II molecules. Cannabinoids abrogate microglial MHC class II expression. Images are
representative of 1 and 25 d after 10 d cannabinoid treatment. Scale bar, 20m.
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number of remyelinating axons ( p 0.001 vs vehicle for the three
agonists) (Fig. 4b). In fact, the percentage of remyelinating axons in
cannabinoid-treated mice was more than twofold higher than in
vehicle-treated mice.
Discussion
The present study reports that functional recovery of TMEV-
infected mice induced by cannabinoid treatment parallels reduc-
tion in CNS inflammation and extensive remyelination.
As evaluated by rotarod performance, treatment with the
cannabinoids, WIN 55,212–2, ACEA and JWH-015, improve
motor coordination of TMEV-infected mice, suggesting the
involvement of both CB receptors on such effect. However,
because JWH-015 has also a low affinity for CB1 receptors, it
cannot be excluded as a putative CB1-mediated effect. In the
chronic relapsing EAE model of MS, Baker et al. (2000) found
reductions on limb spasticity and tremor in mice treated with
CB1 or CB2 selective agonists. Besides, the level of endocan-
nabinoids increased in the spinal cord of diseased mice (Baker
et al., 2001) and changes in the number of CB1 receptors
occurred in motor pathways (Berrendero et al., 2001). To-
gether, these observations suggest that endocannabinoids ton-
ically control spasticity in animal models of MS. Therefore, a
direct action of cannabinoids on the motor system may con-
tribute to the amelioration observed in our study. However,
the maintenance of recovery for at least 25 d after the end of
treatment suggests that effects other than single modulation of
motor pathways are involved.
Cannabinoids may promote long-lasting functional recov-
ery by interfering with the inflammatory demyelinating pro-
cess and by favoring myelin repair. All three agonists reduced
the number of reactive microglia, almost suppressed micro-
glial MHC class II antigen expression, and diminished CD4
T cell infiltration within the spinal cord of TMEV-infected
mice. Therefore, cannabinoid treatment diminished compo-
nents of the MHC class II-restricted CD4 T cell response. In
addition, we show, to our knowledge for the first time, that
cannabinoid treatment favors remyelination in the spinal cord
of TMEV-infected mice. One possibility is that cannabinoids
enhance myelin repair indirectly by inhibiting the immune
response that contributes to demyelination or that hampers
remyelination. Our results showing decreased number of
CD4 T cells in cannabinoid-treated mice support an immu-
nomodulatory mechanism. In accordance with this, depletion
of CD4 T cells enhanced myelin repair (Fiette et al., 1993),
and inhibition of the MHC class II-mediated response using
anti-H-2A antibodies ameliorates TMEV-IDD (Friedmann et
al., 1987). Further support derives from the observation that
interferon-, a cytokine used in MS treatment, inhibits MHC
class II expression (Barna et al., 1989). Therefore, the reduc-
tion in the MHC class II-restricted CD4 T cell response may
be a key event leading to an increased capacity to remyelinate
naked axons in cannabinoid-treated mice. Moreover, canna-
binoids suppress the production of inflammatory molecules
by astrocytes (F. Molina-Holgado et al., 1997, 2002) and mi-
croglial cells (Puffenbarger et al., 2000) perhaps, contributing
to the effects observed in the present study.
The percentage of remyelinating axons in cannabinoid-
treated mice reached values more than twofold higher than in
vehicle-treated mice. In the progressive form of MS, the remyeli-
nation process remains abortive, and although multiple factors
may be involved, the inflammatory environment has been con-
sidered a reliable candidate for such impediment (Noseworthy et
al., 2000). The failure of remyelination in TMEV-IDD, which
resembles progressive MS, may also be related to the inflamma-
tory environment, because the decrease inflammation observed
in cannabinoid-treated mice parallels an increase in remyelina-
Figure 3. Cannabinoids reduce the number of CD4-infiltrated T cells. a, Fluorescence mi-
croscopy images show CD4 T cells infiltrated in the spinal cord of TMEV-infected mice. Note
the clear reduction in CD4-infiltrated T cells in spinal cord from cannabinoid-treated mice.
Scale bar, 8 m. b, Cannabinoid agonist-treated mice show a reduction in the number of
infiltrated CD4 T cells to less than half that of the vehicle-treated group at 1 d after treatment;
this effect is maintained for 25 d (*p 0.05 vs vehicle; **p 0.01 vs vehicle; ***p 0.001 vs
vehicle).
Figure 4. Cannabinoids promote spinal cord remyelination. a, Toluidine blue-stained semi-
thin sections of spinal cord show demyelinated axons (asterisk) in a vehicle-treated mouse and
thin compact myelin sheets in large axons, indicative of remyelination (arrows), in a
WIN55,212–2-treated mouse. Scale bar, 5 m. b, The percentage of remyelinated axons in
cannabinoid-treated animals was more than twofold higher than in vehicle-treated mice
(***p 0.001 vs vehicle).
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tion. The administration of high doses of 9-THC decreased
clinical signs in EAE and also reduced CNS inflammation (Ly-
man et al., 1989). Recent observations indicate that remyelina-
tion progress more efficiently when is associated to the inflam-
matory process (for review, see Franklin, 2002). However, this
occurs mainly in models of toxic demyelination in which the
inflammatory response is a consequence of demyelination and
not its cause, as occurs in immune-mediated demyelination. Un-
der our experimental conditions, downregulation of the inflam-
matory response seems to establish a more favorable CNS envi-
ronment for oligodendroglial cells to resume the myelination
program. Oligodendroglial cells are damaged by inflammatory
stimuli, whereas reduction of inflammation markedly rescues cell
survival (Merril and Benveniste, 1996; Molina-Holgado et al.,
2001). Thus, anti-inflammatory actions of cannabinoids may be
important not only to restrain the demyelination process, but
also to enhance the endogenous reparative remyelination. In ad-
dition, cannabinoids may favor myelin repair directly by acting
on oligodendrocytes. Such hypothesis is supported by the expres-
sion of cannabinoid receptors in oligodendroglial cells and the
protection of progenitors from apoptosis induced by deprivation
of trophic support through a PI3K/Akt-dependent mechanism
(E. Molina-Holgado et al., 2002). Therefore, we suggest that the
effects of cannabinoids on remyelination result from both anti-
inflammatory actions and direct effects on oligodendrocyte sur-
vival and differentiation.
In conclusion, our data show a protective role of cannabinoids
in experimental progressive, inflammatory demyelination. Such
action of cannabinoids is probably exerted at several levels, as
discussed above. The ability of cannabinoids to ameliorate estab-
lished disease may have potential therapeutic implications in de-
myelinating pathologies such as MS, because treatment is started
after the onset of clinical symptomatology. The involvement of
CB2 receptors would enable nonpsychoactive therapy suitable
for long-term use. Moreover, the pharmacological modulation of
endocannabinoid system (Di Marzo et al., 2001) would be a fu-
ture research target for the development of cannabinoid-based
therapy in animal models of MS. Studies in progress are aimed to
evaluate whether cannabinoids are actually involved in oligo-
dendrocyte precursor recruitment and differentiation after
demyelination.
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